{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"13.00","value":"10.00"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"12.00","value":"9.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Measured by the time in days to the first antibiotic dose for bacteremia.","dispersionType":"Full Range","groups":[{"description":"Patients will receive six doses of Uproleselan intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG000","title":"Uproleselan + Standard of Care Melphalan"},{"description":"Patients will receive six doses of placebo intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG001","title":"Placebo + Standard of Care Melphalan"}],"paramType":"MEDIAN","populationDescription":"The number of participants analyzed at each time point may differ from the overall number of participants analyzed because the data was not collected. One patient in the placebo + standard of care melphalan arm was not evaluable for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Through date of discharge (up to be day 18)","title":"Time to First Antibiotics","type":"SECONDARY","unitOfMeasure":"days"}